As of May 29
| -1.35 / -1.96%|
The 33 analysts offering 12-month price forecasts for AstraZeneca have a median target of 73.76, with a high estimate of 98.57 and a low estimate of 57.36. The median estimate represents a +9.19% increase from the last price of 67.55.
The current consensus among 35 polled investment analysts is to Hold stock in AstraZeneca. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.